New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Outlook Therapeutics, Inc.

Contributing Author

Recent Articles by Outlook Therapeutics, Inc.

Sep-03	Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) OTLK GlobeNewswire
Sep-02	Outlook Therapeutics Requests Type A Meeting with FDA OTLK GlobeNewswire
Aug-28	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD OTLK GlobeNewswire
Aug-14	Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update OTLK GlobeNewswire
Jul-24	Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase OTLK GlobeNewswire
Jul-22	Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference OTLK GlobeNewswire
Jul-01	Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer OTLK GlobeNewswire
Jun-18	Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event OTLK GlobeNewswire
Jun-10	Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD OTLK GlobeNewswire
Jun-02	Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD OTLK GlobeNewswire
May-23	Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering OTLK GlobeNewswire
May-22	Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants OTLK GlobeNewswire
May-15	Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update OTLK GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.